Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors, marking one of the largest private financing rounds for a biotech company this year.
The financing was led by Bain Capital's private equity group and included investments from Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan, as well as additional funding from Kailera's founding investors.
The deal highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years.
- The Series B round was announced nearly a year after Kailera's launch with $400 million in funding.
- The investment comes shortly after Pfizer announced plans to acquire Metsera, another privately held obesity drug developer, for $4.9 billion.
Author's summary: Kailera Therapeutics raises $600 million in funding.
More News
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- Signing, Borrower Retention, LOS, QC Audit, AVM Tools; Slowing Economy = Lower Rates
- Human remains found near search for Kada Scott
- Fabrizio Romano has terrible news for Tottenham midfielder
- Manchester United’s stance on Kobbie Mainoo leaving Old Trafford in January revealed